Spotlight – Nash in 2023 and beyond

The first half of this year saw some major ructions in the non-alcoholic steatohepatitis (Nash) space, most notably mid-stage trial successes for 89Bio and Viking Therapeutics. The second half of 2023 will also see some important phase 2 readouts, with Boehringer Ingelheim and Akero aiming to build on somewhat equivocal earlier showings.